The progress of pulmonary artery denervation
Authors:
Open Access
- 31 May 2022
- journal article
- review article
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 29 (3) , 381-387
Abstract
Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by increased pulmonary arterial pressure and pulmonary arterioles remodeling. Some studies have discovered the relationship between sympathetic nerves (SNs) and pathogenesis of PAH. This review is aimed to illustrate the location and components of SNs in the pulmonary artery, along with different methods and effects of pulmonary artery denervation (PADN). Studies have shown that the SNs distributed mainly around the main pulmonary artery (MPA) and pulmonary artery (PA) bifurcation. And the SNs could be destroyed by three ways: the chemical way, the surgical way and the catheter-based way. PADN can significantly decrease pulmonary arterial pressure rapidly, improve hemodynamic varieties, and then palliate PAH. PADN has been recognized as a prospective and effective therapy for PAH patients, especially for those with medication-refractory PAH. However, further enlarged clinical studies are needed to confirm accurate distribution of SNs in the pulmonary artery and the efficacy of PADN. Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by increased pulmonary arterial pressure and pulmonary arterioles remodeling. Some studies have discovered the relationship between sympathetic nerves (SNs) and pathogenesis of PAH. This review is aimed to illustrate the location and components of SNs in the pulmonary artery, along with different methods and effects of pulmonary artery denervation (PADN). Studies have shown that the SNs distributed mainly around the main pulmonary artery (MPA) and pulmonary artery (PA) bifurcation. And the SNs could be destroyed by three ways: the chemical way, the surgical way and the catheter-based way. PADN can significantly decrease pulmonary arterial pressure rapidly, improve hemodynamic varieties, and then palliate PAH. PADN has been recognized as a prospective and effective therapy for PAH patients, especially for those with medication-refractory PAH. However, further enlarged clinical studies are needed to confirm accurate distribution of SNs in the pulmonary artery and the efficacy of PADN.Keywords
This publication has 44 references indexed in Scilit:
- Pulmonary Artery Denervation to Treat Pulmonary Arterial HypertensionJACC, 2013
- Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivoEuroIntervention, 2013
- A Pulmonary Hypertension Model Induced by Continuous Pulmonary Air EmbolizationJournal of Surgical Research, 2011
- Magnetic Nanoparticles and Neurotoxins for Treating Atrial FibrillationCirculation, 2010
- Autonomic Denervation With Magnetic NanoparticlesCirculation, 2010
- A reliable rabbit model for hyperkinetic pulmonary hypertensionThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Lung Vascular Targeting Using Antibody to Aminopeptidase P: CT-SPECT Imaging, Biodistribution and Pharmacokinetic AnalysisJournal of Vascular Research, 2010
- An Experimental Animal Model of Postobstructive Pulmonary HypertensionJournal of Surgical Research, 2008
- Increased Sympathetic Nerve Activity in Pulmonary Artery HypertensionCirculation, 2004
- Experimental Pulmonary Hypertension Produced by Surgical and Chemical Denervation of the Pulmonary VasculatureChest, 1980